Prospective evaluation of serum sarcosine and risk of prostate cancer in the prostate, lung, colorectal and ovarian cancer screening trial

Carcinogenesis

Volumn 34, Issue 10, 2013, Pages 2281-2285

  Koutros, Stella ^a   Meyer, Tamra E ^b   Fox, Stephen D ^c   Issaq, Haleem J ^c   Veenstra, Timothy D ^c   Huang, Wen Yi ^a   Yu, Kai ^a   Albanes, Demetrius ^a   Chu, Lisa W ^d   Andriole, Gerald ^e   Hoover, Robert N ^a   Hsing, Ann W ^d   Berndt, Sonja I ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Office of the Surgeon General of the Army   (United States)

^c SAIC FREDERICK INC   (United States)

^d STANFORD CANCER INSTITUTE   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GLYCINE; SARCOSINE;

ADULT; AGED; ARTICLE; CANCER RISK; CANCER SCREENING; COLORECTAL CANCER; CONTROLLED STUDY; DIABETES MELLITUS; HUMAN; LIQUID CHROMATOGRAPHY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; METABOLOMICS; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; EARLY DETECTION OF CANCER; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK; SARCOSINE; TUMOR MARKERS, BIOLOGICAL;

EID: 84885119983     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt176     Document Type: Article

References (35)

1. Andriole, G.L. et al. (2012) Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J. Natl Cancer Inst., 104, 125-132.
2. Schröder, F.H. et al. (2012) Screening for prostate cancer decreases the risk of developing metastatic disease: findings from the European Randomized Study of Screening for Prostate Cancer (ERSPC). Eur. Urol., 62, 745-752.
3. U.S. Preventive Services Task Force. Screening for prostate cancer, Topic Page 212. http://www.uspreventiveservicestaskforce.org/prostatecancerscreening. htm (28 November 2012, date last accessed).
4. Sreekumar, A. et al. (2009) Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature, 457, 910-914.
5. Cao, D.L. et al. (2011) A multiplex model of combining gene-based, protein- based, and metabolite-based with positive and negative markers in urine for the early diagnosis of prostate cancer. Prostate, 71, 700-710.
6. Cao, D.L. et al. (2011) Efforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of different algorithms of sarcosine in urine. Prostate Cancer Prostatic Dis., 14, 166-172.
7. Colleselli, D. et al. (2010) Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010;58:12-8. Eur. Urol., 58, e51.
8. Jentzmik, F. et al. (2010) Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur. Urol., 58, 12-18.
9. Jentzmik, F. et al. (2011) Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. J. Urol., 185, 706-711.
10. Sreekumar, A. et al. (2010) Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010;58:12-8. Eur. Urol., 58, e29-e30.
11. Stabler, S. et al. (2011) Serum methionine metabolites are risk factors for metastatic prostate cancer progression. PLoS One, 6, e22486.
12. Struys, E.A. et al. (2010) Serum sarcosine is not a marker for prostate cancer. Ann. Clin. Biochem., 47, 282.
13. Wu, H. et al. (2011) GC/MS-based metabolomic approach to validate the role of urinary sarcosine and target biomarkers for human prostate cancer by microwave-assisted derivatization. Anal. Bioanal. Chem., 401, 635-646.
14. Bohm, L. et al. (2012) Plasma sarcosine does not distinguish early and advanced stages of prostate cancer. S. Afr. Med. J., 102, 677-679.
15. Hewavitharana, A.K. (2010) Re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 2010;58:12-8. Eur. Urol., 58, e39-e40.
16. Issaq, H.J. et al. (2011) Is sarcosine a biomarker for prostate cancer? J. Sep. Sci., 34, 3619-3621.
17. Schalken, J.A. (2010) Is urinary sarcosine useful to identify patients with significant prostate cancer? The trials and tribulations of biomarker development. Eur. Urol., 58, 19-20.
18. Hayes, R.B. et al. (2000) Etiologic and early marker studies in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control. Clin. Trials, 21, 349S-355S.
19. Prorok, P.C. et al. (2000) Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control. Clin. Trials, 21, 273S-309S.
20. Meyer, T.E. et al. (2011) A reproducible and high-throughput HPLC/MS method to separate sarcosine from a- and β-alanine and to quantify sarcosine in human serum and urine. Anal. Chem., 83, 5735-5740.
21. Lucarelli, G. et al. (2012) Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml. Prostate, 72, 1611-1621.
22. Kasper, J.S. et al. (2006) A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev., 15, 2056-2062.
23. Bonovas, S. et al. (2004) Diabetes mellitus and risk of prostate cancer: a meta-analysis. Diabetologia, 47, 1071-1078.
24. Leitzmann, M.F. et al. (2008) Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Causes Control, 19, 1267-1276.
25. Wang, T.J. et al. (2011) Metabolite profiles and the risk of developing diabetes. Nat. Med., 17, 448-453.
26. Kasper, J.S. et al. (2008) Hormonal profile of diabetic men and the potential link to prostate cancer. Cancer Causes Control, 19, 703-710.
27. Weiss, J.M. et al. (2008) Endogenous sex hormones and the risk of prostate cancer: a prospective study. Int. J. Cancer, 122, 2345-2350.
28. Lai, G.Y. et al. (2010) Association between C-peptide concentration and prostate cancer incidence in the CLUE II cohort study. Cancer Prev. Res., 3, 1334-1341.
29. Putluri, N. et al. (2011) Metabolomic profiling reveals a role for androgen in activating amino acid metabolism and methylation in prostate cancer cells. PLoS One, 6, e21417.
30. Grossmann, M. et al. (2012) Androgens, diabetes and prostate cancer. Endocr. Relat. Cancer, 19, F47-F62.
31. Watters, J.L. et al. (2009) Cigarette smoking and prostate cancer in a prospective US cohort study. Cancer Epidemiol. Biomarkers Prev., 18, 2427-2435.
32. Kenfield, S.A. et al. (2011) Smoking and prostate cancer survival and recurrence. JAMA, 305, 2548-2555.
33. Enokida, H. et al. (2006) Smoking influences aberrant CpG hypermethylation of multiple genes in human prostate carcinoma. Cancer, 106, 79-86.
34. Shigaki, H. et al. (2012) LINE-1 hypomethylation in noncancerous esophageal mucosae is associated with smoking history. Ann. Surg. Oncol., 19, 4238-4243.
35. Liao, L.M. et al. (2011) LINE-1 methylation levels in leukocyte DNA and risk of renal cell cancer. PLoS One, 6, e27361.